Do you find HPV Today useful? Invite a friend to subscribe! Get a FREE
electronic subscription at

Previous issues:

go to previous issues

Conflict of interest


Suzanne Marie Garland have received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, I also have received funding through my institution to conduct HPV vaccine studies for MSD and GSK. I am a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. Ian H Frazer. The University of Queensland receives royalty payments from the sale of HPV vaccines, of which Ian H Frazer receives a share. He consults for Merck (MSD) on an occasional basis on HPV vaccines. David Regan. CSL Limited is a financial beneficiary of sales of Gardasil® and Cervarix®; bioCSL distributes Gardasil® in Australia and New Zealand. David Regan has consulted for CSL Limited and has received honoraria for these services. Dorotha Gertig, Marian Saville and Julia LM Brotherton have the ARC linkage grant - 'were partner investigators on an Australian Research Council Linkage Grant on which CSL was a partner organisation. Julia LM Brotherton is a chief investigator for RRP surveillance in Australia, which is partially funded by an investigator initiated grant from Merck. Andrew E Grulich: has received honorariums and research funding from CSL Biotherapies; honorariums from Merck; AEG sits on the Australian advisory board for the Gardasil® vaccine. Sepehr Tabrizi was an investigator on a national HPV prevalence study that received partial, equal, and unrestricted funding from CSL Biotherapies and GlaxoSmithKline (GSK). Other authors declared no potential conflict of interest.